IMMUNEERING CORPORATION - CLASS A COMMON STOCK

Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights 

10 May 2022 05:30:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day

05 May 2022 05:50:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference

01 Apr 2022 05:50:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

24 Mar 2022 05:55:00 By Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

10 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in March Investor Conferences

24 Feb 2022 05:50:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in Upcoming Investor Conferences

24 Jan 2022 05:50:00 By Nasdaq GlobeNewswire

Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

18 Jan 2022 05:50:00 By Nasdaq GlobeNewswire

Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event

06 Jan 2022 15:10:00 By Nasdaq GlobeNewswire

Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

03 Jan 2022 05:50:00 By Nasdaq GlobeNewswire

Immuneering Added to the Nasdaq Biotechnology Index

16 Dec 2021 05:50:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in December Investor Conferences

18 Nov 2021 05:35:00 By Nasdaq GlobeNewswire

Immuneering to Participate in Jefferies 2021 London Healthcare Conference

10 Nov 2021 05:50:00 By Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights

09 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

11 Oct 2021 05:50:00 By Nasdaq GlobeNewswire

Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

01 Oct 2021 05:50:00 By Nasdaq GlobeNewswire

Immuneering Announces Inclusion in the Russell 2000® Index

20 Sep 2021 15:10:00 By Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

09 Sep 2021 05:30:00 By Nasdaq GlobeNewswire

Immuneering to Participate in September Investor Conferences

02 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

03 Aug 2021 15:07:00 By Nasdaq GlobeNewswire